Literature DB >> 27167845

Differential Side Effects Profile in mCRPC Patients Treated With Abiraterone or Enzalutamide: A Meta-Analysis of Randomized Controlled Trials.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27167845

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  2 in total

Review 1.  Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.

Authors:  Klara Kvorning Ternov; Jens Sønksen; Mikkel Fode; Henriette Lindberg; Caroline Michaela Kistorp; Rasmus Bisbjerg; Ganesh Palapattu; Peter Busch Østergren
Journal:  BMJ Open       Date:  2019-09-11       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.